Skip to main content

ORIGINAL RESEARCH article

Front. Med.
Sec. Hematology
Volume 11 - 2024 | doi: 10.3389/fmed.2024.1473034

A New Prognostic Scoring System for Newly Diagnosed Multiple Myeloma in the Era of New Drugs

Provisionally accepted
Ye Li Ye Li 1,2Junru Liu Junru Liu 3Jingjing Deng Jingjing Deng 1Yuan Jian Yuan Jian 1Zhang Zhiyao Zhang Zhiyao 1Huixing Zhou Huixing Zhou 1Juan Li Juan Li 3Wenming Chen Wenming Chen 1*
  • 1 Beijing Chaoyang Hospital, Capital Medical University, Beijing, China
  • 2 Peking University People's Hospital, Beijing, Beijing Municipality, China
  • 3 The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong Province, China

The final, formatted version of the article will be published soon.

    Background We developed a new predictive staging system to explore the heterogeneity of survival in newly diagnosed multiple myeloma (NDMM) patients in the real world. Methods In this retrospective study, we evaluated the predictive value of cytogenetic abnormal and clinical data in 375 patients with NDMM at our center. Established a weighted MM prognostic scoring system risk model and validated its predicted PFS and OS by external cohort. Results Elevated lactate dehydrogenase levels (1 point), international staging system stage II/III (1 point), 1q21+ ≥ 52.75% (0.5 point), del (17p) ≥ 3.5% (0.5 point), and t (14;16) ≥ 35.25% (1 point) had independent prognostic significance, and their weighted values were included in the predictive model based on the risk ratio of each risk factor to PFS and OS. Patients were further divided into three risk groups: low (I) (score 0 – 0.5, 16.5%), intermediate (II) (score 1, 46.7%), and high (III) (score 1.5 – 3, 36.8%). In the training cohort, the 3-year PFS was 79.5% vs. 65.3% vs. 40.3% (p < 0.001), and the 3-year OS was 87.7% vs.70.1% vs. 55% (p < 0.001) for the three risk groups. In the external validation cohort, the 3-year PFS was 85.5% vs.61.2% vs. 43.1% (p < 0.001) and the 3-year OS was 91.4% vs.83.5% vs. 56.9% (p < 0.001) for the three risk groups. Conclusion The risk stratification of this model shows good discrimination and calibration, and its application in clinical practice can improve the risk assessment of patients with NDMM and guide personalized treatment strategies.

    Keywords: Multiple Myeloma, cytogenetic abnormal, fish, Cutoff, prognosis

    Received: 30 Jul 2024; Accepted: 02 Oct 2024.

    Copyright: © 2024 Li, Liu, Deng, Jian, Zhiyao, Zhou, Li and Chen. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Wenming Chen, Beijing Chaoyang Hospital, Capital Medical University, Beijing, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.